Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PEG-3350, SODIUM SULFATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM ASCORBATE AND ASCORBIC ACID vs AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Osmotic laxative. Polyethylene glycol (PEG) 3350 and sodium sulfate act as osmotic agents that retain water in the colon, increasing stool water content and inducing diarrhea. Ascorbic acid and sodium ascorbate enhance colonic fluid retention and secretion through organic anion transporters.
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting bacterial protein synthesis.
Bowel preparation before colonoscopy in adults (FDA approved),Bowel preparation for colorectal surgery (off-label),Management of severe constipation (off-label)
Treatment of serious gram-negative bacterial infections (e.g., Pseudomonas aeruginosa, Escherichia coli, Klebsiella species),Used in combination for severe infections such as sepsis, pneumonia, complicated urinary tract infections, and intra-abdominal infections
Adults: 240 m L (or 2 sachets) reconstituted to 1 L water, administered orally or via nasogastric tube, in divided doses (e.g., 240 m L every 10-15 minutes) to a total volume of 1 L, followed by additional clear liquids as needed. For colonoscopy preparation, the typical regimen is a split-dose: first half (500 m L) in the evening before procedure, second half (500 m L) at least 3-5 hours before procedure.
15 mg/kg/day IV divided every 8-12 hours or 15-20 mg/kg IV once daily; typical adult dose: 500-1000 mg IV every 8-12 hours.
PEG 3350: Not applicable (minimal systemic absorption). Ascorbic acid: ~10-20 hours (dose-dependent, renal saturable reabsorption).
The terminal elimination half-life is approximately 2-3 hours in adults with normal renal function. In neonates, it may be prolonged to 4-8 hours. In patients with impaired renal function, half-life can extend to 30-80 hours or more, necessitating dose adjustment based on creatinine clearance.
Not metabolized; excreted unchanged in feces.
Amikacin is minimally metabolized; primarily eliminated unchanged by glomerular filtration.
Primarily fecal (≥96%) as intact PEG 3350; absorbed fraction of electrolytes and ascorbate renally eliminated. Renal excretion of PEG <0.2%.
Amikacin is eliminated primarily by glomerular filtration. Approximately 94-98% of an administered dose is excreted unchanged in the urine within 24 hours in patients with normal renal function. Less than 1% is excreted in bile or feces.
PEG 3350: Negligible; Ascorbic acid: ~25% bound to albumin.
Amikacin has low protein binding, ranging from 0-11%. It binds primarily to albumin, but due to low binding, protein binding alterations do not significantly impact pharmacokinetics.
PEG 3350: ~0 L/kg (confined to GI tract); Ascorbic acid: ~0.4-0.6 L/kg (distributes into total body water).
The volume of distribution is approximately 0.25-0.4 L/kg in adults. It reflects distribution primarily into extracellular fluid. The Vd is increased in conditions such as edema, ascites, and sepsis, and is decreased in dehydration. In neonates, the Vd is larger (0.5-0.6 L/kg) due to higher extracellular fluid volume.
Oral: PEG 3350 <0.06% (systemic); Ascorbic acid: 80-90% at low doses, decreases with high doses (saturable absorption).
Intramuscular: Nearly complete, with bioavailability >90%. Oral: Not bioavailable due to negligible gastrointestinal absorption (<1%). Intravenous: 100%.
Contraindicated in patients with creatinine clearance < 30 m L/min due to risk of fluid and electrolyte disturbances. For GFR 30-60 m L/min: no dose adjustment required but monitor electrolytes and fluid status closely. For GFR > 60 m L/min: no adjustment needed.
Cr Cl 30-60 m L/min: administer every 12-24 hours; Cr Cl 15-29 m L/min: administer every 24-48 hours; Cr Cl <15 m L/min: administer every 48-72 hours. Use therapeutic drug monitoring.
No specific dose adjustment recommended for hepatic impairment. Use with caution in patients with severe hepatic impairment (Child-Pugh class C) due to potential fluid overload and electrolyte imbalances; consider alternative bowel preparation.
No dosage adjustment required for hepatic impairment.
Children (≥6 months to 18 years): For colonoscopy, dose based on age and weight: 6 months to 1 year (7-10 kg): 125 m L (1/4 sachet) in 250 m L water; 1-2 years (10-13 kg): 250 m L (1/2 sachet) in 500 m L water; 2-4 years (13-17 kg): 375 m L (3/4 sachet) in 750 m L water; 4-12 years (17-33 kg): 500 m L (1 sachet) in 1 L water; >12 years: 1 L (2 sachets) in 2 L water. Administer orally in divided doses (e.g., 25-50 m L/kg/h) until clear rectal effluent. Not recommended in infants <6 months.
Neonates: 15-20 mg/kg IV every 24 hours; Infants and children: 15-20 mg/kg IV every 8-24 hours depending on age and renal function. Not to exceed 1.5 g/day.
Elderly patients (≥65 years): No dose adjustment required but use with caution due to increased risk of fluid and electrolyte disturbances, dehydration, and renal impairment. Monitor hydration status, electrolytes, and renal function (creatinine and BUN) before and after administration. Consider split-dose regimen to minimize volume load and ensure adequate hydration.
Reduce initial dose based on renal function; monitor serum creatinine and drug levels; typical starting dose: 7.5 mg/kg IV every 24 hours adjusted for Cr Cl.
None.
Aminoglycosides, including amikacin, are associated with nephrotoxicity and ototoxicity (both auditory and vestibular), which can occur even at therapeutic doses. Risk is increased with prolonged use, higher doses, renal impairment, and concurrent use of other nephrotoxic or ototoxic drugs. Monitoring of renal function and serum drug levels is essential.
Risk of electrolyte abnormalities (especially hypernatremia, hypokalemia) and fluid imbalance,Risk of cardiac arrhythmias, including QT prolongation, in patients with electrolyte disorders or taking QT-prolonging drugs,Risk of renal impairment, especially in patients with pre-existing kidney disease or taking nephrotoxic drugs,Seizures secondary to electrolyte abnormalities,Serious adverse reactions including ulcerative colitis, ischemic colitis, and aspiration
Neurotoxicity (including ototoxicity and nephrotoxicity) may occur. Risk of neuromuscular blockade, especially in patients with neuromuscular disorders or receiving anesthetics. Monitor renal function, audiometric tests, and serum drug concentrations. Use with caution in elderly, dehydrated, or renally impaired patients. Avoid concomitant use of other nephrotoxic or ototoxic agents.
Gastrointestinal obstruction or ileus,Gastric retention,Bowel perforation,Toxic colitis or toxic megacolon,Hypersensitivity to any component,Severe renal impairment (Cr Cl < 30 m L/min),Severe electrolyte abnormalities (e.g., hypernatremia, hypokalemia)
Hypersensitivity to amikacin or any aminoglycoside; history of aminoglycoside-associated ototoxicity or nephrotoxicity; myasthenia gravis (risk of neuromuscular blockade).
Avoid solid food and dairy products during bowel preparation. Only clear liquids (e.g., water, clear broth, apple juice, black coffee/tea) are permitted. Do not consume alcohol.
No significant food interactions. Maintain adequate hydration unless contraindicated. No specific dietary restrictions.
PEG-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid combination is used for bowel cleansing prior to colonoscopy. There are no adequate and well-controlled studies in pregnant women. Animal reproductive studies have not been conducted. Based on the mechanism of action and lack of systemic absorption of the polyethylene glycol and sulfate components, the risk of teratogenicity is considered low. However, dehydration and electrolyte imbalances secondary to the purgative effect could theoretically pose risks, particularly in the first trimester. The FDA pregnancy category is not assigned; however, most sources consider it low risk with cautious use if clearly needed.
Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Aminoglycosides can cause fetal harm when administered to a pregnant woman. There is a potential for fetal ototoxicity and nephrotoxicity. First trimester: Risks unknown but avoid if possible. Second/Third trimester: Use only if clearly needed and if benefit outweighs risk; associated with irreversible bilateral congenital deafness when administered during pregnancy.
Excretion into human milk is unknown for the components. Polyethylene glycol (PEG-3350) is not absorbed systemically after oral administration, so it is unlikely to enter breast milk in significant amounts. Sodium sulfate, sodium chloride, potassium chloride, and ascorbic acid/sodium ascorbate are normal dietary constituents and are present in breast milk at baseline. The M/P ratio has not been established. Use during breastfeeding is generally considered compatible, but the manufacturer recommends caution due to possible gastrointestinal effects in the infant. Ideally, avoid use in nursing mothers unless the benefit outweighs the risk.
Amikacin is excreted in human milk in low concentrations. The M/P ratio is approximately 0.15-0.5. Based on limited data, the dose to the infant is estimated to be <1% of maternal dose. Use with caution in nursing mothers; monitor infant for diarrhea, candidiasis, and potential allergic reactions. Consider the benefits of breast-feeding and the importance of amikacin to the mother.
No pharmacokinetic studies have been performed in pregnant women to determine if dose adjustments are necessary. The components are minimally absorbed or are endogenous substances; therefore, pregnancy-induced changes in gastrointestinal motility or volume of distribution are unlikely to require dose adjustment. However, due to increased risk of dehydration and electrolyte imbalance in pregnancy, some clinicians recommend using a lower dose or a split-dose regimen. The standard adult dose (e.g., 1 liter of solution) may be used if the benefit outweighs the risk, but close monitoring is advised.
Pregnancy may alter pharmacokinetics due to increased volume of distribution and renal blood flow. However, specific dosing adjustments for amikacin in pregnancy are not well established. Monitor serum drug concentrations (peak and trough) to guide dosing, especially in patients with renal impairment or prolonged therapy. Use standard dosing with careful monitoring.
Requires adequate hydration to prevent renal injury; rare cases of osmotic demyelination syndrome reported with rapid correction of hyponatremia; contra indicated in GI obstruction, gastric retention, bowel perforation, toxic colitis, or megacolon.
Avoid concomitant use with other nephrotoxic or ototoxic drugs (e.g., loop diuretics, vancomycin). Monitor peak (25-35 mcg/m L) and trough (<8 mcg/m L) serum levels to guide dosing and reduce toxicity risk. Extended-interval (once-daily) dosing is preferred in many patients; adjust for renal function using ideal body weight. In obese patients, dose based on adjusted body weight. Rapid infusion can cause neuromuscular blockade; use with caution in myasthenia gravis or concurrent neuromuscular blocking agents.
Do not take within 1 hour of other oral medications as absorption may be reduced.,Complete the entire course: split-dose regimen or single dose per prescribing information.,Expect watery stools; stay near a restroom after starting the dose.,Consume only clear liquids during preparation – no red or purple dyes.,Seek medical attention for severe abdominal pain, vomiting, or inability to tolerate the solution.
This medication is given intravenously and will be monitored closely by your healthcare team.,Report any new hearing loss, ringing in the ears, dizziness, or difficulty urinating immediately.,Do not skip or double doses; adhere to the prescribed schedule.,Inform your doctor if you are pregnant, breastfeeding, or have kidney disease.
"Ascorbic acid (vitamin C) can chelate bortezomib, a boronic acid-based proteasome inhibitor, forming a complex that reduces the free concentration of bortezomib in plasma. This chemical interaction primarily occurs in vitro and may also occur in vivo, potentially leading to decreased proteasome inhibition and reduced anticancer efficacy of bortezomib. Clinically, concurrent use of ascorbic acid may compromise bortezomib's therapeutic effect in multiple myeloma or mantle cell lymphoma treatment."
"Ascorbic acid (vitamin C) may reduce the bioavailability of cyclosporine, a calcineurin inhibitor immunosuppressant, potentially leading to decreased serum cyclosporine concentrations and increased risk of transplant rejection. The interaction is thought to occur via alteration of gastrointestinal pH or chelation affecting cyclosporine absorption. Clinical outcomes could include subtherapeutic immunosuppression requiring dosage adjustments."
"Ascorbic acid (vitamin C) can reduce the serum concentration of amphetamine by acidifying the urine, which increases the renal clearance of amphetamine. This occurs because amphetamine is a weak base, and in acidic urine, it is more ionized and less likely to be reabsorbed in the renal tubules, leading to enhanced elimination. Clinically, this may result in decreased amphetamine efficacy, potentially worsening symptoms in patients being treated for attention deficit hyperactivity disorder or narcolepsy."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the renal tubular secretion and potentially reduce the clearance of masoprocol, a dicarboxylic acid derivative used as a chemotherapeutic agent. This interaction could lead to increased systemic exposure to masoprocol, elevating the risk of dose-dependent toxicities such as severe enteritis, myelosuppression, and hepatotoxicity. Given the narrow therapeutic index of masoprocol, even modest elevations in serum levels may result in clinically significant adverse outcomes."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the tubular secretion of mycophenolic acid (MPA) in the renal proximal tubules, leading to reduced renal clearance of MPA. This interaction can result in elevated serum levels of MPA, increasing the risk of dose-related toxicities such as bone marrow suppression (leukopenia, thrombocytopenia), gastrointestinal disturbances, and increased susceptibility to infections. Patients receiving this combination should be closely monitored for signs of MPA toxicity, especially those with pre-existing renal impairment."
"Coadministration of Metocurine, a nondepolarizing neuromuscular blocking agent, with Amikacin, an aminoglycoside antibiotic, may result in enhanced and prolonged neuromuscular blockade. Aminoglycosides can impair acetylcholine release from presynaptic nerve terminals and reduce postsynaptic sensitivity, synergistically augmenting the effects of nondepolarizing agents. This interaction can lead to excessive muscle relaxation, including respiratory muscle paralysis, increasing the risk of apnea and postoperative respiratory depression."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PEG-3350, SODIUM SULFATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM ASCORBATE AND ASCORBIC ACID vs AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
PEG-3350, SODIUM SULFATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM ASCORBATE AND ASCORBIC ACID is a Electrolyte that works by Osmotic laxative. Polyethylene glycol (PEG) 3350 and sodium sulfate act as osmotic agents that retain water in the colon, increasing stool water content and inducing diarrhea. Ascorbic acid and sodium ascorbate enhance colonic fluid retention and secretion through organic anion transporters.. AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting bacterial protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PEG-3350, SODIUM SULFATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM ASCORBATE AND ASCORBIC ACID and AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PEG-3350, SODIUM SULFATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM ASCORBATE AND ASCORBIC ACID is: Adults: 240 m L (or 2 sachets) reconstituted to 1 L water, administered orally or via nasogastric tube, in divided doses (e.g., 240 m L every 10-15 minutes) to a total volume of 1 L, followed by additional clear liquids as needed. For colonoscopy preparation, the typical regimen is a split-dose: first half (500 m L) in the evening before procedure, second half (500 m L) at least 3-5 hours before procedure.. The standard adult dose of AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours or 15-20 mg/kg IV once daily; typical adult dose: 500-1000 mg IV every 8-12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PEG-3350, SODIUM SULFATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM ASCORBATE AND ASCORBIC ACID and AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PEG-3350, SODIUM SULFATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM ASCORBATE AND ASCORBIC ACID is classified as Category A/B. PEG-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid combination is used for bowel cleansing prior to colonoscopy. There are no adequat. AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Aminoglycosides can cause fetal harm when administered to a pregnant . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.